Can stanozolol be safely combined with SARMs like Ostarine or LGD-4033 in the same cycle?

Yes, stanozolol and SARMs occupy mechanistically distinct roles and can be co-administered within a structured protocol. Ostarine or LGD-4033 provide tissue-selective AR modulation while stanozolol contributes nitrogen retention and SHBG displacement through conventional androgen receptor transactivation. Because neither compound aromatises significantly, estrogen management is simplified. Hepatic enzyme monitoring (ALT/AST) is still required due to stanozolol's 17α-alkylated structure.

Which SARM is most commonly paired with oral stanozolol tablets during a cutting phase?

Ostarine (MK-2866) is the most frequently reported SARM partner for oral stanozolol during caloric deficit phases, primarily because its moderate tissue selectivity complements stanozolol's lean-mass preservation signal without adding measurable aromatase substrate. LGD-4033 is the second most cited option, selected when a stronger anabolic background signal is required. Cardarine (GW-501516), though not a true SARM, is also included by some practitioners for metabolic support.

What monitoring should I run when stacking stanozolol tablets with a SARM?

Liver panel testing — specifically ALT and AST — should be conducted at baseline before starting, at the cycle midpoint, and within two weeks post-cycle. Stanozolol's 17α-alkylated processing generates hepatic enzyme elevation risk that SARMs do not independently contribute. Lipid panels (HDL and LDL) are also warranted, as stanozolol reduces HDL levels while most SARMs produce modest additional lipid changes. Testosterone baseline and LH/FSH are standard for post-cycle planning.

What is the advantage of the 10 mg tablet strength when adjusting dose within a SARM combination protocol?

The 10 mg denomination is the lowest single-tablet stanozolol strength commercially available in oral form, making it the most granular adjustment unit in any multi-compound protocol. When a SARM is already contributing anabolic signalling, the practitioner can enter at 10 mg daily stanozolol and increase by one tablet at a time — a precision that a 25 mg or 50 mg tablet does not permit. This matters in SARM stacks where total androgenic exposure is deliberately moderated.

Are NordiStanol tablets supplied in blister strips or a jar, and can they be split for sub-10 mg dosing?

NordiStanol 100-tablet packs are provided in blister-strip format, which preserves individual tablet integrity and supports accurate per-dose tracking across a cycle. Because each tablet contains only 10 mg of stanozolol, splitting is generally unnecessary and not recommended — 10 mg already represents the minimal functional oral increment. The blister format also assists with daily adherence tracking, which is particularly relevant in multi-compound SARM protocols where each compound's schedule must be managed independently. (2) angle_used

Trusted Brand

Nordi Pharma

NordiStanol 10mg/tab 100 Tabletten by Nordi Pharma

Name: NordiStanol 10mg/tab 100 Tablets by Nordi Pharma
Brand: Nordi Pharma
SKU: ORA-STAN-NOR-017
Price: 32.00 EUR
Availability: InStock
Rating: 5 (2 reviews)

5 (2 reviews)

NordiStanol is an oral anabolic preparation delivering stanozolol at 10 mg per tablet across a 100-tablet pack, formulated specifically for practitioners who layer it alongside selective androgen receptor modulators (SARMs) to build multi-pathway anabolic programmes without stacking two fully suppressive androgens. The 10 mg denomination gives precise titration control when fine-tuning the stanozolol contribution within a SARM-inclusive protocol, where total androgenic load management is a primary design constraint. Each production lot undergoes HPLC content-uniformity testing at tablet level alongside LAL endotoxin clearance; GMP-compliant release documentation accompanies every batch.

€32.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers stanozolol at a 10 mg per tablet denomination — ideal as the adjustable variable alongside a fixed SARM dose
Contributes androgen receptor-mediated nitrogen retention that most SARMs cannot fully replicate at moderate exposures
Carries negligible aromatase activity, keeping estrogen management straightforward in SARM-inclusive programmes
HPLC content-uniformity testing at finished-tablet stage ensures each unit reflects declared API content
LAL endotoxin clearance and GMP-compliant batch documentation released per production lot
Blister-strip packaging supports accurate daily dose tracking across complex multi-compound cycles
100-tablet supply provides a sufficient quantity for a full structured SARM combination phase without mid-cycle restocking

Phase	Stanozolol Daily Dose	Note
Entry — SARM-only baseline (Weeks 1–2)	0 mg (no stanozolol)	Establish SARM response and baseline liver enzymes before introducing stanozolol
Introduction — Low-dose add-in (Weeks 3–4)	10 mg (1 tablet)	Single morning tablet; assess ALT/AST at end of Week 4 before escalating
Main phase — Dual-pathway anabolic window (Weeks 5–8)	20 mg (2 tablets)	Split across two daily windows; maintain SARM at unchanged dose
Optional peak — Competition or physique peak (Weeks 9–10)	30 mg (3 tablets)	Only if midpoint liver panel (Week 8) shows ALT/AST within acceptable range; maximum 2 weeks
Taper — Step-down exit (Weeks 11–12)	10 mg → 0 mg	Reduce by one tablet every 3–4 days; continue SARM at original dose if PCT not yet initiated

Key takeaways

Pair NordiStanol with a SARM to target two mechanistically separate anabolic pathways simultaneously.
Choose the 10 mg denomination for single-tablet incremental adjustments within any SARM stack.
Monitor ALT and AST at baseline, midpoint, and post-cycle without exception.
Expect reduced estrogen management complexity compared to testosterone-based stacks.
Confirm per-tablet HPLC verification before adjusting dose variables in a SARM protocol.

Stanozolol as the Androgen Layer in SARM-Inclusive Stacks

NordiStanol defines a category of oral anabolic tools designed for use within multi-compound protocols where a SARM supplies the primary tissue-selective anabolic signal and stanozolol contributes the androgen receptor-mediated nitrogen-retention component that most SARMs cannot fully replicate at moderate exposures. This division of biological roles allows the combined protocol to generate anabolic output across mechanistically distinct intracellular pathways — androgen receptor transactivation from stanozolol and tissue-selective AR modulation from the SARM — without doubling the suppression burden that a second full androgen would impose. Compared to pairing stanozolol with a testosterone ester, a stanozolol-plus-SARM stack carries a materially lower aromatase substrate load, which simplifies estrogen management across the cycle.

Why SARMs and Stanozolol Occupy Complementary Roles

SARMs such as Ostarine (MK-2866) and LGD-4033 activate androgen-sensitive transcription programmes in muscle and bone with reduced engagement of androgenic pathways in non-target tissues. Stanozolol supplies a distinct anabolic signal — principally through enhanced nitrogen retention and SHBG displacement — that reinforces lean tissue preservation during caloric restriction phases where SARMs alone may produce submaximal output. The two compound classes do not share identical receptor-binding kinetics, meaning co-administration produces additive tissue signalling rather than simple redundancy. Practitioners using LGD-4033 at 10 mg daily alongside NordiStanol at 20 mg daily have reported body composition outcomes distinct from either compound used in isolation, though individual response varies and no controlled clinical trial has yet confirmed these observations.

Dosing Precision and Quality Verification in SARM Stacks

Within any SARM combination protocol, controlling the stanozolol variable requires tablet-level content uniformity, because dose adjustments are made in single-tablet increments. Nordi Pharma verifies NordiStanol potency by HPLC analysis applied at the finished-tablet stage — not solely at bulk blend — ensuring that each 10 mg unit reflects the declared API content within the tolerance range specified at batch release. LAL endotoxin testing and GMP-compliant documentation are generated per lot. Hepatic enzyme monitoring (ALT and AST via standard liver panel) remains the primary safety gate when stanozolol is co-administered with any SARM, given that stanozolol's 17α-alkylated structure generates liver enzyme load that most SARMs do not add independently.

Usage

Establish your SARM protocol first — determine the SARM compound, daily dose, and cycle length before introducing NordiStanol, so the stanozolol variable is added to a stable base rather than both compounds starting simultaneously.
Complete baseline bloodwork before tablet day one — ALT, AST, total testosterone, LH, FSH, and full lipid panel provide the reference points needed to interpret any changes at the midpoint liver check.
Begin NordiStanol at one 10 mg tablet per day taken with a meal containing dietary fat, which supports consistent gastrointestinal absorption and reduces the likelihood of gastric discomfort.
At the cycle midpoint, retest ALT and AST; if either value exceeds 2–3× the upper limit of the reference range, reduce the stanozolol daily dose by one tablet immediately and do not escalate further during that cycle.
Distribute your daily dose across two timed windows — for example, one tablet with breakfast and one with an afternoon meal — to maintain a more consistent plasma concentration profile across the active training day.
Plan PCT timing around the longest-acting compound in the overall stack; stanozolol oral clearance resolves within approximately two days after the final tablet, so it does not dictate the PCT start date when a longer-acting SARM is present.

Warnings

Contraindications: NordiStanol is contraindicated in individuals with active hepatic impairment, elevated baseline liver enzymes without identified cause, existing cardiovascular disease involving dyslipidaemia, prostate pathology, or pregnancy. Women of childbearing potential should not use stanozolol due to virilisation risk. Do not combine with other 17α-alkylated oral compounds during the same cycle.

Side Effects: Hepatic enzyme elevation (ALT and AST) is the primary dose-dependent risk of 17α-alkylated stanozolol. HDL cholesterol reduction occurs predictably and should be quantified by lipid panel. Joint dryness affecting elbows, knees, and shoulders is reported by a proportion of users; this effect is more pronounced during caloric restriction. Androgenic effects including acne, scalp hair thinning, and mood changes are possible, particularly at doses above 20 mg daily.

Monitoring: Liver function tests (ALT, AST, ALP) and a full lipid panel at baseline, at the cycle midpoint, and within two weeks post-cycle are the minimum monitoring framework. Blood pressure measurement is advisable monthly given stanozolol's haematological activity. When stanozolol is used alongside a suppressive SARM, include LH, FSH, and total testosterone in the post-cycle panel to characterise HPG axis recovery trajectory.

PCT: Stanozolol contributes to HPG axis suppression, though the degree varies with dose and cycle duration. When co-administered with a suppressive SARM, plan PCT timing and compound selection based on the full suppressive load of both agents. Standard SERMs (Tamoxifen or Clomiphene) are used in most post-cycle recovery protocols; the specific duration and dosing should reflect bloodwork rather than calendar convention.

Frequently asked questions

Can stanozolol be safely combined with SARMs like Ostarine or LGD-4033 in the same cycle?: Yes, stanozolol and SARMs occupy mechanistically distinct roles and can be co-administered within a structured protocol. Ostarine or LGD-4033 provide tissue-selective AR modulation while stanozolol contributes nitrogen retention and SHBG displacement through conventional androgen receptor transactivation. Because neither compound aromatises significantly, estrogen management is simplified. Hepatic enzyme monitoring (ALT/AST) is still required due to stanozolol's 17α-alkylated structure.
Which SARM is most commonly paired with oral stanozolol tablets during a cutting phase?: Ostarine (MK-2866) is the most frequently reported SARM partner for oral stanozolol during caloric deficit phases, primarily because its moderate tissue selectivity complements stanozolol's lean-mass preservation signal without adding measurable aromatase substrate. LGD-4033 is the second most cited option, selected when a stronger anabolic background signal is required. Cardarine (GW-501516), though not a true SARM, is also included by some practitioners for metabolic support.
What monitoring should I run when stacking stanozolol tablets with a SARM?: Liver panel testing — specifically ALT and AST — should be conducted at baseline before starting, at the cycle midpoint, and within two weeks post-cycle. Stanozolol's 17α-alkylated processing generates hepatic enzyme elevation risk that SARMs do not independently contribute. Lipid panels (HDL and LDL) are also warranted, as stanozolol reduces HDL levels while most SARMs produce modest additional lipid changes. Testosterone baseline and LH/FSH are standard for post-cycle planning.
What is the advantage of the 10 mg tablet strength when adjusting dose within a SARM combination protocol?: The 10 mg denomination is the lowest single-tablet stanozolol strength commercially available in oral form, making it the most granular adjustment unit in any multi-compound protocol. When a SARM is already contributing anabolic signalling, the practitioner can enter at 10 mg daily stanozolol and increase by one tablet at a time — a precision that a 25 mg or 50 mg tablet does not permit. This matters in SARM stacks where total androgenic exposure is deliberately moderated.
Are NordiStanol tablets supplied in blister strips or a jar, and can they be split for sub-10 mg dosing?: NordiStanol 100-tablet packs are provided in blister-strip format, which preserves individual tablet integrity and supports accurate per-dose tracking across a cycle. Because each tablet contains only 10 mg of stanozolol, splitting is generally unnecessary and not recommended — 10 mg already represents the minimal functional oral increment. The blister format also assists with daily adherence tracking, which is particularly relevant in multi-compound SARM protocols where each compound's schedule must be managed independently. (2) angle_used

Manufacturer

The personnel behind NordiStanol's tablet formulation represent a cross-disciplinary team whose combined expertise spans pharmaceutical chemistry, QC analytical method development, and the regulatory science of low-strength oral androgenic preparations — a specialisation set that directly shapes the product's content-uniformity outcomes. Within Nordi Pharma's development structure, the staff responsible for API qualification, granulation optimisation, and compression parameter control operate under documented competency frameworks requiring demonstrated proficiency in HPLC method validation and LAL testing interpretation specific to orally administered anabolic compounds. This team-level investment in specialist knowledge — rather than generic pharmaceutical production experience — is the operational basis for the batch-by-batch HPLC release data and GMP-compliant documentation that accompanies every NordiStanol lot reaching the market.

Product details

Brand	Nordi Pharma
Active ingredient	stanozolol
Also known as	Winstrol, Stano, Stanozolol Tablets, NordiStanol, Nordi Pharma Winstrol
Strength	10 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-STAN-NOR-017

Reviews

5/5

2 reviews

Rating: 5 out of 5 starsironVerified purchaseJul 20, 2026
winstrol did its job
Last 6 weeks of my cut at 50mg ed. Came in really dry, joints were manageable with fish oil and glucosamine, dropped from 96kg to 91kg over the full cut period. Vascularity was the best it's ever been on stage. Packaging spot on, no issuse at delivery end whatsoever
Rating: 5 out of 5 starsfortitudeJun 2, 2026
Proper cutting compound
50mg tabs ed for 5 weeks pre-comp, hardness and dryness came in week 3. zero water retention, abs visible at around 9% bf. Took extra joint support and was fine. Bloodwork showed hematocrit at 48% which is fine. HDL dipped a bit but boucned back 6 weeks post cycle. Reordered already

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

Strombafort 10mg/tab 100 Tablets by Balkan Pharmaceuticals

Strombafort is an oral anabolic steroid built on a stanozolol backbone — a 17α-methylated, A-ring-modified dihydrotestosterone (DHT) derivative — formulated at 10 mg per tablet and supplied in a pack of 100 tablets by Balkan Pharmaceuticals. Its defining pharmacological character stems from partial androgen receptor (AR) agonism combined with an inability to aromatise, making estrogenic activity structurally impossible for this molecule. Every batch of Strombafort is released only after HPLC assay confirmation of active stanozolol content and LAL-method endotoxin testing; GMP-certified production at the Chișinău facility underpins both identity and purity.

€32.00

Pro-Winstrol 20mg/tab 50 Tablets by Beligas Pharmaceuticals

HPLC Verified

Pro-Winstrol 20mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Winstrol by Beligas Pharmaceuticals delivers stanozolol at 20 mg per tablet in a 50-tablet oral format, defined primarily by its predictable pharmacokinetic profile: an oral half-life of approximately 9 hours that supports structured twice-daily dosing for stable plasma concentrations. Compared to injectable stanozolol suspension — which carries a half-life closer to 24 hours — the oral form enables more responsive dose adjustments across a cycle. Chromatographic content verification is applied to every production batch; each tablet's active stanozolol quantity is confirmed against certified reference standards prior to lot release.

€45.00

StanoTrex Tablets 10mg/tab 100 Tablets by Concentrex Labs

Pharma Grade

StanoTrex Tablets 10mg/tab 100 Tabletten by Concentrex Labs

StanoTrex Tablets deliver stanozolol in a discrete oral tablet format at 10 mg per unit — a concentration engineered for straightforward dose calibration while the compound's systemic absorption, secured by 17α-alkylation, ensures reliable plasma exposure despite hepatic first-pass transit. Oral stanozolol undergoes partial attenuation through liver metabolism compared to aqueous injectable suspension, yet the alkylated molecular structure preserves sufficient active compound to maintain consistent anabolic signalling across each dosing interval. Each 100-tablet jar is manufactured within a GMP-certified facility, with finished-tablet potency confirmed by HPLC quantification against a certified stanozolol reference standard before any lot clears for release.

€36.00

Winstrol 50 10mg/tab 100 Tablets by Dragon-Pharma

Batch Tested

Winstrol 50 10mg/tab 100 Tabletten by Dragon-Pharma

Dragon-Pharma Winstrol 50 delivers stanozolol in 10 mg oral tablets — a precision-dosed format specifically suited to managing the receptor-level adaptation that occurs when androgen signalling is sustained beyond its productive window. The 10 mg per-tablet format allows incremental dose adjustment as practitioners respond to early signs of diminishing receptor responsiveness, a clinical reality that makes low-denomination tablets more strategically valuable than high-concentration alternatives during extended use. Each 100-tablet batch clears HPLC content verification and GMP Standard-certified process controls before a release certificate is issued, confirming declared potency as a measured fact rather than a label assumption.

€30.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00